Emergent Biosolutions is pulling its application for a lower-dose version of Narcan as the company moves to make a standard dose of the opioid overdose reversal medication available without a prescription.
The Food and Drug Administration announced Thursday it’s withdrawing agency approval of a supplemental new drug application for
a 2 mg nasal spray version of Emergent’s Narcan, according to a Federal Register notice.
Emergent already sells a 4 mg version of Narcan, a brand-name version of naxalone, to reverse an opioid disorder. According to the package insert, providers should only prescribe the 2 mg spray to patients ...